A phase I and pharmacokinetic study of intraperitoneal topotecan

Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5–30 mg/m(2)) for pharmacokinetic analysis. Results: Dose limiting toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofstra, L S, Bos, A M E, Vries, E G E de, Zee, A G J van der, Beijnen, J H, Rosing, H, Mulder, N H, Aalders, J G, Willemse, P H B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363984/
https://www.ncbi.nlm.nih.gov/pubmed/11742479
http://dx.doi.org/10.1054/bjoc.2001.2161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363984/
https://www.ncbi.nlm.nih.gov/pubmed/11742479
http://dx.doi.org/10.1054/bjoc.2001.2161

Ejemplares similares